Jeff Yass’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-12,700
| Closed | -$62K | – | 10911 |
|
|
2016
Q4 | $62K | Buy |
+12,700
| New | +$65K | ﹤0.01% | 9239 |
|
|
2016
Q2 | – | Sell |
-17,000
| Closed | -$97K | – | 10096 |
|
|
2016
Q1 | $97K | Buy |
+17,000
| New | +$119K | ﹤0.01% | 8448 |
|
|
2015
Q4 | – | Sell |
-10,800
| Closed | -$199K | – | 10639 |
|
|
2015
Q3 | $199K | Buy |
+10,800
| New | +$208K | ﹤0.01% | 8713 |
|
|
2015
Q2 | – | Sell |
-21,700
| Closed | -$381K | – | 10888 |
|
|
2015
Q1 | $381K | Buy |
21,700
+5,400
| +33% | +$90.7K | ﹤0.01% | 7588 |
|
|
2014
Q4 | $261K | Sell |
16,300
-28,200
| -63% | -$378K | ﹤0.01% | 8373 |
|
|
2014
Q3 | $560K | Buy |
44,500
+8,200
| +23% | +$117K | ﹤0.01% | 6999 |
|
|
2014
Q2 | $567K | Sell |
36,300
-22,700
| -38% | -$334K | ﹤0.01% | 7232 |
|
|
2014
Q1 | $775K | Sell |
59,000
-28,500
| -33% | -$446K | ﹤0.01% | 5974 |
|
|
2013
Q4 | $1.41M | Buy |
87,500
+300
| +0.3% | +$4.78K | ﹤0.01% | 4889 |
|
|
2013
Q3 | $1.45M | Sell |
87,200
-3,400
| -4% | -$50.3K | ﹤0.01% | 4664 |
|
|
2013
Q2 | $912K | Buy |
+90,600
| New | +$952K | ﹤0.01% | 5144 |
|
Other funds holding OSIR
Jeff Yass's OSIR Position: Q2 2019 in Review
Jeff Yass sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 175,223 shares — an estimated $3.33M sold.
Jeff Yass first reported a position in OSIR in Q2 2013 and held it in 16 quarters. The position peaked at $3.65M in Q4 2014. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Jeff Yass reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Jeff Yass sold 175,223 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $3.33M.
- Jeff Yass first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 16 quarters.
- Jeff Yass's Osiris Therapeutics, Inc. Common Stock position peaked at $3.65M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.